Kevin Scaife

Mr. Kevin Scaife


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2023 in Food and Chemical Toxicology
Verified
Journal Article
Closed access
KSKevin Scaife
Kevin Scaife
TVTrung D. Vo
Trung D. Vo
YDYvonne Dommels
Yvonne Dommels
ELElisa Leune
Elisa Leune
KAKaj Albermann
Kaj Albermann
LPLucie Pařenicová
Lucie Pařenicová

22 April 2024 in Regulatory Toxicology and Pharmacology
Verified
Journal Article
Closed access
KSKevin Scaife
Kevin Scaife
STSteve L. Taylor
Steve L. Taylor
LPLucie Pařenicová
Lucie Pařenicová
RGRichard E. Goodman
Richard E. Goodman
TVTrung D. Vo
Trung D. Vo
YDYvonne Dommels
Yvonne Dommels

20 October 2024 in Journal of Applied Toxicology
Verified
Journal Article
Closed access
KSKevin Scaife
Kevin Scaife
KPKirt R. Phipps
Kirt R. Phipps
DSDaniella Scalise
Daniella Scalise
OPOlivér Polgár
Olivér Polgár

27 April 2025 in Journal of Applied Toxicology
Verified
Journal Article
Open access
KPKirt R. Phipps
Kirt R. Phipps
SPSachin Patel
Sachin Patel
KSKevin Scaife
Kevin Scaife
THToby Holmes
Toby Holmes
AŠAlica Šoltésová
Alica Šoltésová
CJChristel Jørgensen
Christel Jørgensen
Gastrointestinal health is one of the fastest growing areas in the food and beverage industry, as its importance to overall health and well‐being is becoming increasingly recognized. Immunoglobulins play a key role in protecting the gastrointestinal tract, and nonbovine sources of immunoglobulins (including camel milk, which has a long history of consumption in East Africa and Asia) are increasing in popularity in Western countries as functional foods, particularly for individuals with allergies or intolerances to cow's milk. The physiological benefits of consuming certain heavy‐chain immunoglobulins from camel milk relate to the binding domains of camelid single‐domain antibodies; thus, a novel binding protein termed “immunoglobulin G (IgG) binding protein LT” (a dimer of two camelid single‐domain antibody protein sequences) has been developed for use in food and beverage products, to provide some of the physiological benefits attributed to consuming camel milk, on an industrial scale. To support the safety of IgG binding protein LT for such use, a comprehensive safety assessment (in silico allergenicity assessment, in vitro genotoxicity studies [bacterial reverse mutation test and in vitro mammalian cell micronucleus test], and a 90‐day gavage toxicity study in rats) was conducted. The in silico allergenicity assessment results demonstrate that IgG binding protein LT is highly unlikely to pose a risk of allergenic cross‐reactivity, and there was no evidence of genotoxicity in vitro. There were no test article–related effects in the 90‐day toxicity study. These data demonstrate the safety of IgG binding protein LT for its intended uses in foods and beverages.